Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Natac Natural Ingredients S.A. is a specialty chemicals company focused on the research, development, and production of sustainable natural ingredients derived from botanicals and fish. It specializes in plant extracts from sources such as olives, grapes, rhodiola, saffron, artichoke, and other Mediterranean plants, offering standardized extracts, full spectrum ingredients, branded products like ENDOLIVE and POMOLIVE, concentrated extracts, and custom molecules for pharmaceuticals. These ingredients support health benefits including cardiovascular health, healthy aging, immunomodulation, digestive health, metabolic syndrome management, and more, enabling substantiated claims in end products. Natac employs advanced, eco-friendly extraction methods, organic certification at its Hervás facility, and rigorous quality controls like the HABOID botanical identity system, alongside certifications such as GMP, FSSC 22000, ISO 14001, Halal, and Kosher. Serving nutraceutical, food, pharmaceutical, and cosmetic sectors across Europe, Asia, Latin America, and North America, the company emphasizes traceable sourcing, whole-plant utilization, and sustainability to meet demand for natural, high-potency solutions in functional foods and dietary supplements. Headquartered in Getafe, Spain.
€0.57
+€0.00 (+0.00%)
EOD Jun 23, 2026 · Twelve Data
12.91% operating margin is respectable but not wide. ROIC at 3.89%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 35.0%, still solid.
At 626x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Negative free cash flow of -€3M. The business is consuming cash, not generating it.
626.4x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€36M
▲ +35.0% YoY
Net Income (TTM)
€397K
▼ -93.7% YoY
Op. Margin
12.91%
▲ +1.2pp YoY
ROIC
3.89%
▲ +1.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€3M
▼ -60.9% YoY
Op. Cash Flow (TTM)
€5M
▼ -52.5% YoY
Net Debt
€79M
Cash & Equiv.
€702K
3Y CAGR: +222.0%
Continue Research